Towards a new EU pharmaceutical strategy

Author (Person)
Author (Corporate)
Series Title
Series Details PE737.129
Publication Date December 2022
Content Type


The European Commission plans to launch its revised EU pharmaceutical package in the first quarter of 2023. Ahead of its release, two recent STOA studies offer insight to inform upcoming Parliamentary discussions. Fragmentation of EU health research and development, lack of transparency and a translation gap between public investment and clinical output are among the weaknesses identified. Possible solutions include the creation of large-scale European biomedical infrastructure, and a series of targeted strategies to improve EU health research coordination and reprioritise areas of unmet therapeutic need.

Source Link
Alternative sources
Subject Categories ,
Subject Tags
International Organisations